Core Viewpoint - The article highlights the significant issue of post-treatment hyperpigmentation (referred to as "返黑") in the Chinese medical aesthetics market, with a reported 28% recurrence rate after light therapy treatments, which undermines the initial goals of skin whitening and brightening [3][5][6]. Group 1: Market Insights - The compound annual growth rate (CAGR) for post-treatment care products in China's medical aesthetics sector is projected to reach 30% from 2022 to 2026, with the market size expected to hit 25.38 billion yuan by 2026 [3]. - A survey by Estée Lauder in 2024 indicates that 84% of consumers participate in light therapy projects, making it the dominant choice in the market [3]. - The white paper reveals that 95% of consumers pursue light therapy primarily for skin whitening, yet over 25% experience worsening pigmentation [5][6]. Group 2: Consumer Challenges - The article discusses the psychological impact of post-treatment hyperpigmentation, with 90% of affected individuals feeling distressed, and 24% experiencing extreme distress [11][12]. - The unique skin characteristics of Chinese consumers, such as more active melanocytes and weaker skin barriers, contribute to a higher incidence of post-inflammatory hyperpigmentation (PIH) [7][9]. - Many consumers lack consistent sun protection awareness, particularly during autumn and winter, which exacerbates the issue of post-treatment pigmentation [9]. Group 3: Solutions and Innovations - Clinique has introduced a systematic solution called "妆械联合" (makeup and medical device integration) to address the complexities of post-treatment skin care, combining medical-grade products with daily skincare routines [14][16]. - The CX series, a new line of medical device products, includes a collagen-based wound care solution that enhances healing and skin barrier repair [17]. - The upgraded 302 Photon Laser Bottle aims to prevent post-treatment pigmentation and enhance daily whitening, utilizing a targeted formula that has shown promising clinical results [19][20]. Group 4: Industry Evolution - The article emphasizes the need for a paradigm shift in the medical aesthetics industry from short-term treatments to long-term management strategies, as highlighted by Clinique's approach [24][26]. - Clinique's integration of medical device technology with skincare formulations represents a significant advancement in addressing the specific needs of Asian skin types [26]. - The white paper serves as a scientific guide for consumers, aiming to establish industry standards and provide a comprehensive solution for pre-, intra-, and post-treatment care [22][24].

昨日（2 0 2 5年5月1日），雅诗兰黛集团发布2 0 2 5财年第三季度财报，中国大陆市场逆势交出 关键答卷—— 实现中个位数增长。至此，中国市场在过去的四个季度中，有三个季度实现市 场份额的扩大 。 尽管其全球净销售额同比下滑1 0%至3 5 . 5亿美元（约合人民币2 5 8 . 1 4亿），但这一成绩在亚洲 旅游零售渠道收缩、消费情绪疲软的背景下尤显韧性。 面 对 关 税 政 策 的 不 确 定 性 ， 雅 诗 兰 黛 集 团 首 度 明 确 表 态 ： 持 续 多 年 的 全 球 供 应 链 区 域 化 布 局，是应对贸易环境波动的重要资产。财报强调，通过灵活调整生产与物流网络，集团有能力 缓冲高关税对成本端的冲击 。 " 2 0 2 5财年第三季度，我们实现了有机销售额的预期，并超出了盈利预期。 "对于上任以来的 首份成绩单，雅诗兰黛集团总裁兼首席执行官司泰峰（St é p h a n e d e La Fa v e ri e）表示满意。 那么，雅诗兰黛集团是如何在变革中稳住基本盘？中国市场的战略地位又将如何重塑其全球版 图？ | 截图自雅诗兰黛集团2025财年第三季度财报 | | --- | ...